News and Comments

Alnylam: Some Acted Without Listening and Some Listened But Did Not Believe

  Thursday, October 06, 2016

Following recent reports of new onset or worsening peripheral neuropathy in patients with ATTR amyloidosis with cardiomyopathy (hATTR-CM) treated with Alnylam’s (ALNY) RNAi –based drug revusiran, The firm requested that the Data Monitoring Committee (DMC) review the reports and the Clinical trial data on an unblinded basis. After reviewing the reports, the DMC advised suspending the dosing of revusiran.   More...

Regulus Offers Proof of Concept and Feasibility with Its HCV RNA Targeted Drug

  Wednesday, February 17, 2016

Regulus Pharmaceuticals (RGLS) a biopharmaceutical company that discovers, designs and develop treatments targeting microRNAs announced interim results from one of the company's ongoing Phase 2 studies of its hepatitis C virus (HCV) product RG-101.   More...

The FDA Approval Of Kynamro™ Promises ISIS A Bright Future Read Also about ALNY; Sarepta, SNY

  Thursday, January 31, 2013

 More...

Illumina, Roche and Fairness

  Thursday, February 09, 2012

Illumina (ILMN) is occupying the center stage these days. Roche’s persistent attempts to acquire ILMN, has opened investors’ eyes on the importance of this firm’s technology in moving away from the road of stagnation to that of innovation. Innovation is the insurance that guarantees the survival and growth of the drug companies in the future that has already begun. Illumina’s technologies and marketed state-of-the-art sequencers and gene analyzers have been a major contributor to the flourishing of information about the origins of diseases at the molecular level.  This capability, which lured Roche, was overlooked by Wall Street investors who have recently caused a selloff in the stock for theorized reasons. The real value of Illumina resides in its indispensability as the cornerstone of future advancement in medical diagnosis and treatment. With all the new-targeted drugs on the market and in the firms’ pipelines, the current diagnostic and treatment statuses are still far from perfect. More...

Monster Blockbuster Anti-Cholesterol Drugs In Biotechs’ Pipelines

  Wednesday, August 31, 2011

The new biological science is evolving at the speed of light. As a matter of fact, the bright penetrating light of the genomic revolution is effectively reaching the dark corners where the utmost reality remained hidden since millions of years. The new light enabled the insight to match the sight in divulging the buried secrets of body at the molecular level. With the most advanced tools ever created by human minds, scientists have reached a stage where they can spend much less effort in solving much more puzzles on the road towards solving the problems of diseases at their root-origin. The successful are those researchers who keep their eyes open and their minds prepared. More...


Recent Postings


Archive


Tags

Illumina (ILMN) REGULUS (RGLS) Agenus (AGEN) Sarepta (SRPT) Elan (ELN) Sangamo (SGMO) ACADIA (ACAD) Auspex (ASPX) Sequenom (SQNM) NEUROCRINE (NBIX) Biogen Idec (BIIB) Bristol-Myers Squibb (BMY) LEXICON (LXRX) KERYX (KERX) Sanofi (SNY) Exelixis (EXEL) SUNESIS PHARMACEUTICALS (SNSS) JUNO (JUNO) galapagos (GLPG) Galena (GALE) Revlimid (lenolidamide) ABBVIE (ABBV) ImmunoGen (IMGN) Prolor Biotech (PBTH) KITE (KITE) Intercept (ICPT) Theravance Bio Pharma (TBPH) Bellicum (BLCM) Aimmune Therapeutics (AIMT) Editas (EDIT) VANDA (VNDA) CEMPRA (CEMP) Velcade (bortezomib) Roche (RHHBY) Array Pharmaceuticals (ARRY) Spike Therapeutics (ONCE) Vertex (VRTX) AstraZeneca (AZN) ISIS (ISIS) Theravance (THRX) Inovio (INO) Advaxis (ADXS) Sanofi (SNA) PORTOLA (PTLA) Incyte (INCY) JOUNCE THERAPEUTICS (JNCE) NANTKWEST (NK) Human Longevity (HLI) Tysabri GUARDIAN HEALTH Micromet (MITI) Multiple Myeloma Anadys (ANDS) Intrexon (XON) Adaptimmune (ADAP) SERES THERAPEUTICS (MCRB) Ridaforolimus Dendreon (DNDN) Zerenex Abbott Laboratories (ABT) Seattle Genetics (SGEN) ZALTRAP™ Dynavax (DVAX) CompuGen (CGEN) Merck (MRK) Idenix (IDIX) Telaprevir GlaxoSmithKline (GSK) Global Cell Therapeutics (GBT) Jazz Pharmaceuticals (JAZZ) TOKAI (TKAOI) Ariad (ARIA) NOVOCURE (NVCR) HALOZYME (HALO) Endometrial Cancer Intermune (ITMN) Genentech Anacor (ANAC) NEKTAR (NKTR)) Xoma (XOMA) Regeneron (REGN) Pluristem (PSTI) AERIE PHARMACEUTICALS ADVENTRIX (ANX) Onyx (ONXX) ARCA (ABIO) Herceptin AGOS (ARGS) BIOMARIN (BMRN) Benlysta (belimumab) Mirati Therapeutics (MRTX) Rapamune INNOVIVA (INVA) Cytokinetics (CYTK) Ziofpharm (ZIOP) Valeant Pharmaceuticals International (VRX) Sanofi-Aventis (SAN) MODERNA C4 Therapeutics PTC Therapeutics (PTCT) Amgen (AMGN) Alnylam (ALNY) Vitae Pharmaceuticals (VTAE) OSI (OSIP) Alder Biopharmaceuticals (ALDR) IDERA (IDRA) OncoCyte (OCX) CRISPR Therapeutics (CRSP) Agenus (AGEN ARGOS (ARGS) Biocryst (BCRX) Prosensa (RNA) Ocular Therapeutix (OCUL) Ionis (IONS) Roche (ROCHE) Gilead (GILD) Human Genome Sciences (HGSI) SYNTA (SNTA) RenenxBio (RGNX) Trastuzumab-DM1